(Finance) – The US pharmaceutical company Pfizer made a deal for acquire ReViral for a total consideration of up to $ 525 million. The acquired company is a biopharmaceutical company focused on the discovery, development and commercialization of novel antiviral therapies that target the respiratory syncytial virus (RSV). It is a respiratory pathogen that can lead to severe and life-threatening lower respiratory tract infections in high-risk populations (including young children, immunocompromised individuals and the elderly). It is estimated to cause infections in approximately 64 million people, causing approximately 160,000 deaths globally each year.
“At Pfizer we have a strong commitment in the fight against infectious diseasesas demonstrated recently by our supply of the first authorized vaccine and the first oral therapy to fight Covid-19 – said the CEO Albert Bourla – We are continuing to grow our pipeline, through our research and development efforts, such as our experimental RSV vaccine programs, as well as strategic investments in companies such as ReViral, with a focus on end-to-end capabilities for help protect patients from serious illness, hospitalization and death. “
On a day when US indices are trading close to par, the performance of Pfizerwhich stands at 55.29 with an increase of 4.57%. At the operational level, the session is expected to continue under the banner of bull with resistance seen at 56.26 and later at 59.11. Support at 53.41.